<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316833</url>
  </required_header>
  <id_info>
    <org_study_id>ROLEX_2017</org_study_id>
    <nct_id>NCT03316833</nct_id>
  </id_info>
  <brief_title>The Rolex Registry</brief_title>
  <acronym>Rolex</acronym>
  <official_title>The ROLEX Registry (Revascularization Of LEft Main With Resolute onyX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and efficacy of the&#xD;
      new-generation zotarolimus-eluting stent Resolute Onyx in the treatment of unprotected left&#xD;
      main coronary artery disease (ULMCAD), both isolated or in association with two- or&#xD;
      three-vessel coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ROLEX study is a prospective, non-randomized, European, multi-center registry.&#xD;
&#xD;
      Four hundred and fifty patients with unprotected left main coronary artery disease (ULMCAD)&#xD;
      will be enrolled at up to 40 European sites. The main objective of the study is to assess the&#xD;
      safety and efficacy of the new-generation zotarolimus-eluting stent Resolute Onyx in the&#xD;
      treatment of ULMCAD, both isolated or in association with two- or three-vessel coronary&#xD;
      artery disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion failure</measure>
    <time_frame>12 months</time_frame>
    <description>composite of cardiac death, target vessel myocardial infarction and ischemia-driven target lesion revascularization</description>
  </primary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx</intervention_name>
    <description>Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score &lt;33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with unprotected left main coronary artery disease up to intermediate&#xD;
        anatomical complexity (defined by a SYNTAX score &lt;33), considered amenable for percutaneous&#xD;
        coronary intervention (PCI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject &gt; 18 years old&#xD;
&#xD;
          -  ULMCAD with angiographic diameter stenosis &gt;50% (if 50-70% evidence of FFR &lt;0.80 or&#xD;
             IVUS minimal lumen area &lt;6.0 mm2 is recommended.&#xD;
&#xD;
          -  Silent ischemia, stable angina, unstable angina or non-ST elevation myocardial&#xD;
             infarction&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with follow-up for at least 2&#xD;
             years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical exclusion criteria:&#xD;
&#xD;
               -  Prior PCI on the left main trunk or prior CABG.&#xD;
&#xD;
               -  Concomitant indication to cardiac surgery (severe heart valve disease etc.)&#xD;
&#xD;
               -  Cardiogenic Shock (Killip&gt;2)&#xD;
&#xD;
               -  Severe renal insufficiency (GFR &lt;30 ml/min)&#xD;
&#xD;
               -  Known impaired left ventricular function (left ventricular ejection fraction&#xD;
                  &lt;30%)&#xD;
&#xD;
               -  Inability to tolerate or comply with dual antiplatelet therapy for at least 1&#xD;
                  year&#xD;
&#xD;
               -  Pregnancy or intention to become pregnant&#xD;
&#xD;
               -  Life expectancy less than 1 year&#xD;
&#xD;
               -  Other investigational drug or device studies that have not reached their primary&#xD;
                  endpoint&#xD;
&#xD;
          2. Angiographic exclusion criteria:&#xD;
&#xD;
               -  Left main diameter stenosis &lt;50%&#xD;
&#xD;
               -  SYNTAX score &gt;33&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matteo Martinato, PhD</last_name>
    <phone>+390498275646</phone>
    <email>matteo.martinato@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SCTB DCTV</last_name>
    <email>sctb.dctv@unipd.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedale Universit√† Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <email>giuseppe.tarantini.1@unipd.it</email>
    </contact>
    <contact_backup>
      <last_name>Luca Nai Fovino, MD</last_name>
      <email>lucanaifo@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 6, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

